Therapeutic Effect of Vitamin D3 in Multiple Sclerosis Patients

REFERENCES

• Ascherio, A., Munger, K. (2008). Epidemiology of multiple sclerosis: From risk factors to prevention. Semin. Neurol. 28:17–28.
   PubMed Web of Science ®Google Scholar
• Becklund, B. R., Severson, K. S., Vang, S. V., Deluca, H. F. (2010). UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc. Natl. Acad. Sci. USA 107:6418–6423.
   PubMed Web of Science ®Google Scholar
• Bouillon, R., Eelen, G., Verlinden, L., Mathieu, C., Carmeliet, G., Verstuyf, A. (2006). Vitamin D and cancer. J. Steroid Biochem. Mol. Biol. 102:156–162.
   PubMed Web of Science ®Google Scholar
• Branisteanu, D. D., Waer, M., Sobis, H., Marcelis, S., Vandeputte, M., Bouillon, R. (1995). Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3. J. Neuroimmunol. 61:151–160.
   PubMed Web of Science ®Google Scholar
• Brosnan, C. F., Raine, C. S. (1996). Mechanisms of immune injury in multiple sclerosis. Brain Pathol. 6:243–257.
   PubMed Web of Science ®Google Scholar
• Cantorna, M. T., Hayes,C. E., DeLuca, H. F. (1996). 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 93:7861–7864.
   PubMed Web of Science ®Google Scholar
• Cantorna, M. T., Woodward, W. D., Hayes, C. E., DeLuca, H. F. (1998). 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J. Immunol. 160:5314–5319.
   PubMed Web of Science ®Google Scholar
• Correale, J., Gilmore, W., McMillan, M., Li, S., McCarthy, K., Le, T., Weiner, L. P. (1995). Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J. Immunol. 154:2959–2968.
   PubMed Web of Science ®Google Scholar
• Dhib-Jalbut, S. (2007). Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 68, S13–21; discussion S43–54.
   PubMed Web of Science ®Google Scholar
• Goldberg, P., Fleming, M. C., Picard, E. H. (1986). Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med. Hypotheses 21:193–200.
   PubMed Web of Science ®Google Scholar
• Imitola, J., Chitnis, T., Khoury, S. J. (2005). Cytokines in multiple sclerosis: From bench to bedside. Pharmaco.l Ther. 106:163–177.
   PubMed Web of Science ®Google Scholar
• Johns, L. D., Flanders, K. C., Ranges, G. E., Sriram, S. (1991). Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1. J. Immunol. 147:1792–1796.
   PubMed Web of Science ®Google Scholar
• Kimball, S. M., Ursell, M. R., O’Connor, P., Vieth, R. (2007). Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 86:645–651.
   PubMed Web of Science ®Google Scholar
• Korn, T. (2008). Pathophysiology of multiple sclerosis. J. Neurol. 255 Suppl 6:2–6.
   PubMedGoogle Scholar
• Lemire, J. M., Adams, J. S., Kermani-Arab, V., Bakke, A. C., Sakai, R., Jordan, S. C. (1985). 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J. Immunol. 34:3032–3035.
   Google Scholar
• Lemire, J. M., Archer, D. C. (1991). 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 87:1103–1107.
   PubMed Web of Science ®Google Scholar
• Mahon, B. D., Gordon, S. A., Cruz, J., Cosman, F., Cantorna, M. T. (2003). Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 134:128–132.
   PubMed Web of Science ®Google Scholar
• Matheu, V., Back, O., Mondoc, E., Issazadeh-Navikas, S. (2003). Dual effects of vitamin D-induced alteration of TH1/TH2 cytokine expression: Enhancing IgE production and decreasing airway eosinophilia in murine allergic airway disease. J Allergy Clin. Immunol. 112:585–592.
   PubMed Web of Science ®Google Scholar
• McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H. P., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., Sandberg-Wollheim, M., Sibley, W., Thompson, A., van den Noort, S., Weinshenker, B. Y., Wolinsky, J. S. (2001). Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50:121–127.
   PubMed Web of Science ®Google Scholar
• Mokhtarian, F., Shi, Y., Shirazian, D., Morgante, L., Miller, A., Grob, D. (1994). Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis. J. Immunol. 152:6003–6010.
   PubMed Web of Science ®Google Scholar
• Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S., Ascherio, A. (2006). Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832–2838.
   PubMed Web of Science ®Google Scholar
• Munger, K. L., Zhang, S. M., O’Reilly, E., Hernan, M. A., Olek, M. J., Willett, W. C., Ascherio, A. (2004). Vitamin D intake and incidence of multiple sclerosis. Neurology 62:60–65.
   PubMed Web of Science ®Google Scholar
• Muthian, G., Raikwar, H. P., Rajasingh, J., Bright, J. J. (2006). 1,25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J. Neurosci. Res. 83: 1299–1309.
   PubMed Web of Science ®Google Scholar
• Myhr, K. M. (2009). Vitamin D treatment in multiple sclerosis. J. Neurol. Sci. 286:104–108.
   Google Scholar
• Nashold, F. E., Hoag, K. A., Goverman, J., Hayes, C. E. (2001). Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 119, 16–29.
   PubMed Web of Science ®Google Scholar
• Nashold, F. E., Miller, D. J., Hayes, C. E. (2000). 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 103:171–179.
   PubMed Web of Science ®Google Scholar
• Nieves, J., Cosman, F., Herbert, J., Shen, V., Lindsay, R. (1994). High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44:1687–1692.
   PubMed Web of Science ®Google Scholar
• Nordvik, I., Myhr, K.M., Nyland, H., Bjerve, K.S. (2000). Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol. Scand. 102: 143–149.
   PubMed Web of Science ®Google Scholar
• Ozgocmen, S., Bulut, S., Ilhan, N., Gulkesen, A., Ardicoglu, O., Ozkan, Y. (2005). Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J. Bone Miner. Metab. 23:309–313.
   PubMed Web of Science ®Google Scholar
• Pelfrey, C. M., Rudick, R. A., Cotleur, A. C., Lee, J. C., Tary-Lehmann, M., Lehmann, P. V. (2000). Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J. Immunol. 165:1641–1651.
   PubMed Web of Science ®Google Scholar
• Pierrot-Deseilligny, C. (2009). Clinical implications of a possible role of vitamin D in multiple sclerosis. J. Neurol. 256:1468–1479.
   PubMed Web of Science ®Google Scholar
• Provvedini, D. M., Tsoukas, C. D., Deftos, L. J., Manolagas, S. C. (1983). 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221:1181–1183.
   PubMed Web of Science ®Google Scholar
• Raine, C. S., Wu, E J., Ivanyi, J., Katz, D., Brosnan, C. F. (1996). Multiple sclerosis: a protective or a pathogenic role for heat shock protein 60 in the central nervous system? Lab. Invest. 75:109–123.
   Google Scholar
• Simon, K.C., Munger, K.L., Xing, Y., Ascherio, A. (2010). Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult. Scler. 16:133–138.
   PubMed Web of Science ®Google Scholar
• Smolders, J., Damoiseaux, J., Menheere, P., Hupperts, R. (2008a). Vitamin D as an immune modulator in multiple sclerosis: A review. J. Neuroimmunol. 194:7–17.
   PubMed Web of Science ®Google Scholar
• Smolders, J., Menheere, P., Kessels, A., Damoiseaux, J., Hupperts, R. (2008b). Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult. Scler. 14:1220–1224.
   PubMed Web of Science ®Google Scholar
• Smolders, J., Menheere, P., Thewissen, M., Peelen, E., Tervaert, J. W., Hupperts, R., Damoiseaux, J. (2010). Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J. Ster. Biochem.Mol. Biol.121:243–246.
   PubMed Web of Science ®Google Scholar
• Soilu-Hänninen, M., Airas, L., Mononen, I., Heikkilä, A., Viljanen, M., Hänninen, A. (2005). 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 11:266–271.
   PubMed Web of Science ®Google Scholar
• Thorbecke, G. J., Umetsu, D. T., deKruyff, R. H., Hansen, G., Chen, L. Z., Hochwald, G. M. (2000). When engineered to produce latent TGF-beta1, antigen specific T cells down regulate Th1 cell-mediated autoimmune and Th2 cell-mediated allergic inflammatory processes. Cytokine Growth Factor Rev. 11:89–96.
   PubMedGoogle Scholar
• van der Mei, I. A., Ponsonby, A. L., Blizzard, L., Dwyer, T. (2001). Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20:168–174.
   PubMed Web of Science ®Google Scholar
• van der Mei, I. A., Ponsonby, A. L., Engelsen, O., Pasco, J. A., McGrath, J. J., Eyles, D. W., Blizzard, L., Dwyer, T., Lucas, R., Jones, G. (2007). The high prevalence of vitamin D insufficiency across Australian populations is only partly explained by season and latitude. Environ. Health Perspect. 115:1132–1139.
   PubMed Web of Science ®Google Scholar
• Van Etten, E., Branisteanu, D. D., Overbergh, L., Bouillon, R., Verstuyf, A., Mathieu, C. (2003). Combination of a 1,25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone 32:397–404.
   PubMed Web of Science ®Google Scholar
• Veldman, C. M., Cantorna, M. T., DeLuca, H. F. (2000). Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 37:334–338.
   Google Scholar
• Wingerchuk, D. M., Lesaux, J., Rice, G. P., Kremenchutzky, M., Ebers, G. C. (2005). A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psych. 76:1294–1296.
   PubMed Web of Science ®Google Scholar
• Winquist, R. J., Kwong, A., Ramachandran, R., Jain, J. (2007). The complex etiology of multiple sclerosis. Biochem. Pharmacol. 74:1321–1329.
   Google Scholar
• Zuvich, R. L., McCauley, J. L., Pericak-Vance, M. A., Haines, J. L. (2009). Genetics and pathogenesis of multiple sclerosis. Semin. Immunol. 21:328–333.
   PubMed Web of Science ®Google Scholar